Octreotide inhibits the growth and development of three types of experimental liver metastases.
A study was performed to assess the effects of octreotide on the growth and development of liver metastases in rats. Tumour was induced by intraportal injection of three tumorigenic cell lines (the fibrosarcoma HSN and colonic adenocarcinomas K12/Tr and WB2054M) in syngeneic rats. Octreotide treatment (2 micrograms subcutaneously for 3 or 4 weeks) was started 18 h and 1 week after tumour induction; a delay in treatment of 1 week allowed micrometastases to develop. Treatment with octreotide significantly (P < 0.001) reduced the median hepatic replacement of liver by tumour compared with that of control rats given saline (controls: HSN 76.4 per cent, K12/Tr 17.5 per cent, WB2054M 43.9 per cent; octreotide treatment delayed 18 h: HSN 2.7 per cent, K12/Tr 0.6 per cent, WB2054M 1.3 per cent; octreotide treatment delayed 1 week: HSN 9.3 per cent, K12/Tr 2.5 per cent, WB2054M 2.3 per cent). These results clearly indicate that octreotide significantly inhibits the growth and development of experimental liver metastases. Further studies are required both to delineate the mechanism of action and to investigate these effects in a clinical setting.
Davies
N
N
Department of Surgery, University of Liverpool, UK.
Kynaston
H
H
Yates
J
J
Nott
D M
DM
Nash
J
J
Taylor
B A
BA
Jenkins
S A
SA
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D008114:Liver Neoplasms, Experimental / Q000503:physiopathology / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D014407:Tumor Cells, Cultured
D015282:Octreotide